High Growth Tech Stocks In South Korea August 2024

The South Korean market has climbed 1.9% in the last 7 days and 3.8% over the past year, with earnings forecasted to grow by an impressive 28% annually. In this favorable environment, identifying high-growth tech stocks that are poised to capitalize on these trends can be crucial for investors seeking robust returns.

Top 10 High Growth Tech Companies In South Korea

Name	Revenue Growth	Earnings Growth	Growth Rating
ALTEOGEN	48.67%	72.95%	★★★★★★
IMLtd	20.76%	106.30%	★★★★★★
Bioneer	22.49%	89.69%	★★★★★★
NEXON Games	31.70%	66.31%	★★★★★★
Seojin SystemLtd	34.20%	58.67%	★★★★★★
EuBiologics	28.05%	93.39%	★★★★★★
Devsisters	26.11%	65.92%	★★★★★★
AmosenseLtd	24.29%	55.45%	★★★★★★
Park Systems	22.50%	37.52%	★★★★★★
UTI	103.56%	122.67%	★★★★★★

Click here to see the full list of 49 stocks from our KRX High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩15.86 billion.

Operations: ALTEOGEN Inc. generates revenue primarily from its biotechnology segment, amounting to ₩121.09 billion. The company's focus areas include long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.

ALTEOGEN's recent approval of Tergase® by the MFDS marks a significant milestone, leveraging its proprietary Hybrozyme™ Technology to deliver a product with over 99% purity and lower immunogenicity. This approval is expected to drive revenue growth at an impressive 48.7% annually, outpacing the market's 10.6%. Additionally, earnings are forecasted to grow at 72.9% per year, significantly higher than the KR market's 28.3%. Despite some shareholder dilution in the past year and high volatility in share price, ALTEOGEN’s transition to a commercial-stage company positions it well for future expansion in various medical fields beyond dermal filler removal.

• Get an in-depth perspective on ALTEOGEN's performance by reading our health report here.

• Explore historical data to track ALTEOGEN's performance over time in our Past section.

ABL Bio (KOSDAQ:A298380)

Simply Wall St Growth Rating: ★★★★★☆

Overview: ABL Bio Inc., a biotech research company, focuses on developing therapeutic drugs for immuno-oncology and neurodegenerative diseases, with a market cap of ₩1.50 trillion.

Operations: ABL Bio Inc. specializes in creating therapeutic drugs targeting immuno-oncology and neurodegenerative diseases. The company operates with a market cap of ₩1.50 trillion.

ABL Bio, a prominent player in the biotech sector, is set to experience substantial growth with earnings projected to surge by 93.89% annually and revenue expected to climb at an impressive 33.5% per year, outpacing the broader Korean market's 10.6%. The company recently raised KRW 139.99B through a private placement involving significant investors like Korea Development Bank and Atinum Growth Fund. Notably, ABL Bio has invested heavily in R&D expenses, underscoring its commitment to innovation within the biotech industry.

• Take a closer look at ABL Bio's potential here in our health report.

• Gain insights into ABL Bio's historical performance by reviewing our past performance report.

Lunit (KOSDAQ:A328130)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Lunit Inc. develops and provides AI-based software solutions for cancer screening, diagnosis, and treatment with a market cap of ₩1.09 billion.

Operations: Lunit Inc. generates revenue primarily from its healthcare software segment, which contributed ₩19.25 million. The company focuses on AI-based solutions for cancer-related applications.

Lunit's AI-driven innovations, particularly in healthcare, are propelling its growth trajectory. The company's revenue is forecasted to grow at 51.3% annually, significantly outpacing the broader market's 10.6%. Its R&D expenses underscore a strong commitment to innovation, with notable achievements like the Lunit INSIGHT CXR demonstrating superior performance in TB detection with an AUC of 0.902 and sensitivity of 89.9%. Additionally, earnings are expected to soar by 101.2% per year over the next three years, reflecting robust future prospects for Lunit in both domestic and international markets.

• Unlock comprehensive insights into our analysis of Lunit stock in this health report.

• Understand Lunit's track record by examining our Past report.

Summing It All Up

• Access the full spectrum of 49 KRX High Growth Tech and AI Stocks by clicking on this link.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com